RxDoctor Payments Data

Dean Sutherland, MD

Neurology · Sarasota, FLNPI 1346251089

Payments from drug & device makers

$70,358in general payments, 2019–2025

Across 573 payments — averaging $122.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$31K
  • Amneal Pharmaceuticals LLC$13K
  • Acorda Therapeutics, Inc$12K
  • Sunovion Pharmaceuticals Inc.$7K
  • AbbVie$2K
  • Abbott$615
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$30,75477%
  • Food & beverage$8,98623%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,358 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$451,940
Medicare patients
1,332
Services billed
23,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa454$880,002
NuplazidPimavanserin Tartrate104$760,566
AustedoDeutetrabenazine40$284,961
IngrezzaValbenazine Tosylate23$180,499
NeuproRotigotine84$126,996
InbrijaLevodopa34$102,776
GocovriAmantadine Hcl32$92,413
NourianzIstradefylline20$85,426
Austedo XrDeutetrabenazine11$76,577
Carbidopa-LevodopaCarbidopa/Levodopa1,372$49,405
Rasagiline Mesylate183$41,239
BotoxOnabotulinumtoxina19$21,055
Rivastigmine64$16,546
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone34$15,033
AmantadineAmantadine Hcl195$12,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$12,875$880,002454 claims
Acadia Pharmaceuticals IncNuplazid$265$760,566104 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$204$361,53851 claims
Neurocrine Biosciences, Inc.Ingrezza$460$180,49923 claims
UCB, Inc.Neupro$525$126,99684 claims
Acorda Therapeutics, IncInbrija$11,668$102,77634 claims
MDD US Operations, LLCGocovri$30,952$92,41332 claims
Kyowa Kirin, Inc.Nourianz$198$85,42620 claims
AbbVieBotox$1,876$21,05519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →